Early-phase AML CAR-T and CAR NK clinical trials targeting CD33, CD123, and NKG2D are ongoing, with creative solutions that actively seek to overcome therapeutic obstacles [61]. This evidence concerns the gene IL3RA and acute myeloid leukemia.